SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase

Leukemia. 2022 Dec;36(12):2927-2930. doi: 10.1038/s41375-022-01734-7. Epub 2022 Oct 21.

Authors

Sandra Huber¹, Torsten Haferlach¹, Manja Meggendorfer¹, Stephan Hutter¹, Gregor Hoermann¹, Constance Baer¹, Wolfgang Kern¹, Claudia Haferlach²

Affiliations

¹ MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany.
² MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, 81377, Munich, Germany. claudia.haferlach@mll.com.

No abstract available

Publication types

Letter

MeSH terms

Humans
Leukemia, Myeloid, Acute* / genetics
MDS1 and EVI1 Complex Locus Protein
Mutation
Phosphoproteins / genetics
RNA Splicing Factors / genetics

Substances

RNA Splicing Factors
Phosphoproteins
SF3B1 protein, human
MECOM protein, human
MDS1 and EVI1 Complex Locus Protein